Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CFO Sells $246,749.39 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CFO Jeffrey V. Poulton sold 967 shares of the company’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $246,749.39. Following the completion of the sale, the chief financial officer now owns 32,786 shares of the company’s stock, valued at approximately $8,366,003.62. This represents a 2.86 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Alnylam Pharmaceuticals Trading Up 0.8 %

Shares of Alnylam Pharmaceuticals stock opened at $252.49 on Friday. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The business’s 50 day moving average is $254.04 and its 200-day moving average is $263.12. The stock has a market cap of $32.69 billion, a P/E ratio of -116.36 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.94 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Huntington National Bank increased its position in Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 45 shares during the last quarter. Hollencrest Capital Management bought a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $29,000. Larson Financial Group LLC increased its holdings in shares of Alnylam Pharmaceuticals by 187.2% during the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 73 shares during the last quarter. R Squared Ltd bought a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at $33,000. Finally, Colonial Trust Co SC acquired a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at $35,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have issued reports on ALNY. Wolfe Research cut Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday, November 12th. Piper Sandler reiterated an “overweight” rating and issued a $296.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. Needham & Company LLC restated a “buy” rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, February 14th. Canaccord Genuity Group upped their price target on shares of Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the company a “buy” rating in a report on Tuesday. Finally, StockNews.com downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 9th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have issued a buy rating to the company. According to data from MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $299.48.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.